| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/14/2023 | — | JP Morgan | Downgrades | Neutral → Underweight | |
| 09/13/2023 | 1150% | Benchmark | → $23 | Reiterates | Buy → Buy |
| 08/25/2023 | 443.48% | Canaccord Genuity | → $10 | Assumes | → Buy |
| 08/10/2023 | 389.13% | TD Cowen | $15 → $9 | Maintains | Outperform |
| 08/10/2023 | 796.74% | DA Davidson | $35 → $16.5 | Maintains | Buy |
| 08/08/2023 | 1150% | Benchmark | → $23 | Reiterates | Buy → Buy |
| 06/21/2023 | 443.48% | Stifel | $17 → $10 | Downgrades | Buy → Hold |
| 05/26/2023 | 552.17% | JP Morgan | $13 → $12 | Maintains | Neutral |
| 05/18/2023 | 1150% | Benchmark | → $23 | Reiterates | Buy → Buy |
| 05/11/2023 | 1802.17% | DA Davidson | → $35 | Reiterates | → Buy |
| 03/28/2023 | 878.26% | Canaccord Genuity | → $18 | Reiterates | → Buy |
| 03/20/2023 | — | Exane BNP Paribas | Upgrades | Underperform → Neutral | |
| 03/14/2023 | 1150% | Benchmark | → $23 | Reiterates | → Buy |
| 03/01/2023 | 1802.17% | DA Davidson | $32 → $35 | Maintains | Buy |
| 02/28/2023 | 1150% | Benchmark | → $23 | Reiterates | → Buy |
| 02/16/2023 | 715.22% | Cowen & Co. | $20 → $15 | Maintains | Outperform |
| 11/23/2022 | 932.61% | Goldman Sachs | $22 → $19 | Maintains | Buy |
| 11/09/2022 | 497.83% | JP Morgan | $22 → $11 | Downgrades | Overweight → Neutral |
| 11/09/2022 | 1639.13% | DA Davidson | $31 → $32 | Maintains | Buy |
| 09/28/2022 | 1584.78% | DA Davidson | $30 → $31 | Maintains | Buy |
| 09/16/2022 | 1150% | Piper Sandler | $20 → $23 | Maintains | Overweight |
| 09/16/2022 | 1530.43% | DA Davidson | $25 → $30 | Maintains | Buy |
| 08/16/2022 | 1095.65% | Goldman Sachs | $25 → $22 | Maintains | Buy |
| 08/10/2022 | 986.96% | Piper Sandler | $22 → $20 | Maintains | Overweight |
| 08/10/2022 | 1258.7% | DA Davidson | $24 → $25 | Maintains | Buy |
| 07/08/2022 | 1095.65% | Piper Sandler | $24 → $22 | Maintains | Overweight |
| 06/30/2022 | 986.96% | Canaccord Genuity | $22 → $20 | Maintains | Buy |
| 05/12/2022 | 1204.35% | DA Davidson | $35 → $24 | Maintains | Buy |
| 05/11/2022 | 1258.7% | Goldman Sachs | $29 → $25 | Maintains | Buy |
| 05/11/2022 | 1204.35% | Piper Sandler | $26 → $24 | Maintains | Overweight |
| 04/28/2022 | 1313.04% | Piper Sandler | $31 → $26 | Maintains | Overweight |
| 03/14/2022 | 1150% | Benchmark | $18 → $23 | Maintains | Buy |
| 03/11/2022 | 1204.35% | JP Morgan | → $24 | Initiates Coverage On | → Overweight |
| 02/23/2022 | 1802.17% | DA Davidson | $32 → $35 | Maintains | Buy |
| 01/07/2022 | — | William Blair | Initiates Coverage On | → Outperform | |
| 12/23/2021 | — | Raymond James | Initiates Coverage On | → Market Perform | |
| 11/10/2021 | 1639.13% | DA Davidson | $26 → $32 | Maintains | Buy |
| 10/08/2021 | 1693.48% | Stifel | → $33 | Initiates Coverage On | → Buy |
| 10/04/2021 | 1639.13% | Cowen & Co. | → $32 | Initiates Coverage On | → Outperform |
| 08/11/2021 | 1313.04% | DA Davidson | $17.5 → $26 | Maintains | Buy |
| 07/19/2021 | 1095.65% | Jefferies | → $22 | Initiates Coverage On | → Buy |
| 07/01/2021 | 1584.78% | Goldman Sachs | → $31 | Initiates Coverage On | → Buy |
| 06/24/2021 | 1204.35% | Piper Sandler | → $24 | Initiates Coverage On | → Overweight |
| 06/15/2021 | 1041.3% | Canaccord Genuity | → $21 | Initiates Coverage On | → Buy |
| 06/01/2021 | 851.09% | DA Davidson | $16 → $17.5 | Maintains | Buy |
What is the target price for Beauty Health (SKIN)?
The latest price target for Beauty Health (NASDAQ: SKIN) was reported by JP Morgan on November 14, 2023. The analyst firm set a price target for $0.00 expecting SKIN to fall to within 12 months (a possible -100.00% downside). 17 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Beauty Health (SKIN)?
The latest analyst rating for Beauty Health (NASDAQ: SKIN) was provided by JP Morgan, and Beauty Health downgraded their underweight rating.
When is the next analyst rating going to be posted or updated for Beauty Health (SKIN)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Beauty Health, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Beauty Health was filed on November 14, 2023 so you should expect the next rating to be made available sometime around November 14, 2024.
Is the Analyst Rating Beauty Health (SKIN) correct?
While ratings are subjective and will change, the latest Beauty Health (SKIN) rating was a downgraded with a price target of $0.00 to $0.00. The current price Beauty Health (SKIN) is trading at is $1.84, which is out of the analyst's predicted range.